Latest Headlines

  1. Impilo Therapeutics Launches To Enable Nucleic Acid-Based Medicines To Effectively Treat Solid Tumor Cancers 8/15/2023

    Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the mission to enable nucleic acid-based medicines to effectively treat solid tumor cancers.

  2. Parexel And Partex Announce Innovative Alliance Leveraging Artificial Intelligence And Big Data To Accelerate Drug Discovery And Development 8/15/2023

    Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and Partex, the first Data-to-Drugs pharma platform, today announced a preferred strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios.

  3. FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) For Phase 2 Study Of Oral TNF-α Inhibitor MYMD-1 In Rheumatoid Arthritis (RA) 8/14/2023

    MyMD Pharmaceuticals, Inc. a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug Application (IND) to evaluate the safety, efficacy, pharmacodynamics and pharmacokinetics of oral TNF-α inhibitor MYMD-1 in patients with active rheumatoid arthritis (RA).

  4. Research Alert: City Of Hope Scientists Uncover New Active Regions On Cell Surface Receptor, Expanding Scope For Drug Targets To Treat Heart Disease 8/14/2023

    Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, have uncovered new molecular targets on a cell receptor that play a major role in cardiovascular regulation.

  5. CAS And Molecule.one Announce A Strategic Collaboration To Accelerate Drug Discovery 8/11/2023

    CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules.

  6. Tiny Antibodies Hold Big Promise For Cancer Treatment 8/10/2023

    Using antibodies derived from alpacas, a University of Kentucky research team has developed a tool that could lead to new therapies to stop the growth of several types of cancer.

  7. Real-World Evidence Shows Healthcare Providers Use C2N Diagnostics’ PrecivityAD Blood Test To Help Affirm Alzheimer’s Disease Diagnosis And Change Drug Treatment Decisions 8/8/2023

    C2N Diagnostics, a leader in advanced brain health diagnostics, says new research posted in the online version of Annals of Clinical and Translational Neurology (and soon in print form) affirms the clinical utility of its PrecivityAD blood test, which healthcare providers use to help diagnosis Alzheimer’s disease (AD)

  8. Nephron Works To Resolve Nationwide Drug Shortage By Producing Vital Medications 8/8/2023

    Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

  9. Astex Expands Drug Discovery Collaboration With MSD 8/8/2023

    Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA).

  10. NS-018, An Investigational Treatment For Myelofibrosis, Receives Orphan Drug Designation From The European Commission 8/8/2023

    NS Pharma, Inc. announced today that the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).